文献速递淋巴瘤

阿利塞替布与研究者选择(选定单药)方案治疗复发或难治性外周T细胞淋巴瘤的随机III期研究

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2019-02-01

该开放标签、首次在此类患者中开展的随机III期试验纳入271例复发/难治性外周T细胞淋巴瘤成人患者,1:1随机接受阿利塞替布口服或研究者选择的单药 comparator(普拉曲沙、吉西他滨或罗米地辛)。因独立数据监查委员会认为阿利塞替布达到PFS优效性的概率低而提前终止入组。中心评估的总缓解率阿利塞替布组33% vs comparator组45%(OR 0.60;95%CI 0.33-1.08),中位PFS 115天 vs 104天(HR 0.87;95%CI 0.637-1.178),阿利塞替布未达统计学显著优效。

要点

  • 阿利塞替布组总缓解率33% vs comparator组45%(OR 0.60;95%CI 0.33-1.08),差异未达统计学显著。
  • 中位PFS阿利塞替布组115天 vs comparator组104天(HR 0.87;95%CI 0.637-1.178)。
  • 两组2年总生存率均为35%,阿利塞替布未显著优于comparator。

核心结论

  • 在复发/难治性外周T细胞淋巴瘤患者中,阿利塞替布未在统计学上显著优于comparator组。

研究设计与样本

  • 开放标签、首次在此类患者中开展的随机III期试验,纳入复发/难治性外周T细胞淋巴瘤成人患者(既往≥1线治疗),1:1随机分配。
  • 阿利塞替布组口服50 mg每日两次(第1-7天;21天周期);comparator组为研究者选择的单药:普拉曲沙30 mg/m2静脉(每周一次,共6周;7周周期),或吉西他滨1,000 mg/m2静脉、或罗米地辛14 mg/m2静脉(第1、8、15天;28天周期)。
  • 2012年5月至2014年10月共随机分配271例患者(阿利塞替布组n=138;comparator组n=133)。
  • 肿瘤组织(疾病亚型)和影像学由独立中心审查评估;主要终点为总缓解率和无进展生存期(PFS);计划两次中期分析和一次最终分析。

主要发现

  • 因独立数据监查委员会认为在全入组下阿利塞替布达到PFS优效性的概率低,入组提前终止。
  • 中心评估的总缓解率阿利塞替布组33% vs comparator组45%(OR 0.60;95%CI 0.33-1.08)。
  • 中位PFS阿利塞替布组115天 vs comparator组104天(HR 0.87;95%CI 0.637-1.178)。
  • 最常见不良事件为贫血(阿利塞替布组53% vs comparator组34%)和中性粒细胞减少(阿利塞替布组47% vs comparator组31%)。
  • 导致研究药物停药的事件发生率阿利塞替布组9% vs comparator组14%;26例研究期间死亡中5例被认为与治疗相关(阿利塞替布组11例中3例;comparator组15例中2例);两组2年总生存率均为35%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 入组因独立数据监查委员会认为阿利塞替布达到PFS优效性的概率低而提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this open-label, first-in-setting, randomized phase III trial was to evaluate the efficacy of alisertib, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). PATIENTS AND METHODS: Adult patients with relapsed/refractory PTCL-one or more prior therapy-were randomly assigned 1:1 to receive oral alisertib 50 mg two times per day (days 1 to 7; 21-day cycle) or investigator-selected single-agent comparator, including intravenous pralatrexate 30 mg/m2 (once per week for 6 weeks; 7-week cycle), or intravenous gemcitabine 1,000 mg/m2 or intravenous romidepsin 14 mg/m2 (days 1, 8, and 15; 28-day cycle). Tumor tissue (disease subtype) and imaging were assessed by independent central review. Primary outcomes were overall response rate and progression-free survival (PFS). Two interim analyses and one final analysis were planned. RESULTS: Between May 2012 and October 2014, 271 patients were randomly assigned (alisertib, n = 138; comparator, n = 133). Enrollment was stopped early on the recommendation of the independent data monitoring committee as a result of the low probability of alisertib achieving PFS superiority with full enrollment. Centrally assessed overall response rate was 33% for alisertib and 45% for the comparator arm (odds ratio, 0.60; 95% CI, 0.33 to 1.08). Median PFS was 115 days for alisertib and 104 days for the comparator arm (hazard ratio, 0.87; 95% CI, 0.637 to 1.178). The most common adverse events were anemia (53% of alisertib-treated patients v 34% of comparator-treated patients) and neutropenia (47% v 31%, respectively). A lower percentage of patients who received alisertib (9%) compared with the comparator (14%) experienced events that led to study drug discontinuation. Of 26 on-study deaths, five were considered treatment related (alisertib, n = 3 of 11; comparator, n = 2 of 15). Two-year overall survival was 35% for each arm. CONCLUSION: In patients with relapsed/refractory PTCL, alisertib was not statistically significantly superior to the comparator arm.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. O'Connor OA, Özcan M, Jacobsen ED, et al. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019. PMID: 30707661. doi:10.1200/JCO.18.00899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。